<DOC>
	<DOCNO>NCT01698645</DOCNO>
	<brief_summary>National multicenter , prospective , observational study cancer patient chronic background pain breakthrough pain PecFent® prescribe pragmatic condition specialist treatment cancer pain condition . • Study objectives include assessment early treatment satisfaction .</brief_summary>
	<brief_title>Patient Satisfaction Quality Life Impact - PecFent®</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Adult ( age ≥18 year ) cancer Taking least 60 mg oral morphine sulfate equivalent per day chronic background pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>quality life</keyword>
	<keyword>PecFent</keyword>
	<keyword>Lazanda</keyword>
	<keyword>fentanyl</keyword>
	<keyword>intranasal</keyword>
	<keyword>breakthrough cancer pain</keyword>
</DOC>